Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination

被引:31
|
作者
Bridle, Byram W. [1 ]
Nguyen, Andrew [2 ]
Salem, Omar [2 ]
Zhang, Liang [2 ]
Koshy, Sandeep [2 ]
Clouthier, Derek [2 ]
Chen, Lan [2 ]
Pol, Jonathan [2 ]
Swift, Stephanie L. [2 ]
Bowdish, Dawn M. E. [2 ]
Lichty, Brian D. [2 ]
Bramson, Jonathan L. [2 ]
Wan, Yonghong [2 ]
机构
[1] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada
[2] McMaster Univ, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada
来源
JOURNAL OF IMMUNOLOGY | 2016年 / 196卷 / 11期
基金
加拿大健康研究院;
关键词
DENDRITIC CELLS; MARGINAL ZONE; MARABA VIRUS; LYMPH-NODES; EFFECTOR; ACTIVATION; EXPRESSION; NAIVE; LOCALIZATION; GENERATION;
D O I
10.4049/jimmunol.1600106
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Effector T cells (T-EFF) are a barrier to booster vaccination because they can rapidly kill Ag-bearing APCs before memory T cells are engaged. We report in this study that i.v. delivery of rhabdoviral vectors leads to direct infection of follicular B cells in the spleen, where the earliest evidence of secondary T cell responses was observed. This allows booster immunizations to rapidly expand CD8(+) central memory T cells (T-CM) during the acute phase of the primary response that is dominated by TEFF. Interestingly, although the ablation of B cells before boosting with rhabdoviral vectors diminishes the expansion of memory T cells, B cells do not present Ags directly. Instead, depletion of CD11c(+) dendritic cells abrogates secondary T cell expansion, suggesting that virus-infected follicular B cells may function as an Ag source for local DCs to subsequently capture and present the Ag. Because TCM are located within B cell follicles in the spleen whereas TEFF cannot traffic through follicular regions, Ag production and presentation by follicular APCs represent a unique mechanism to secure engagement of TCM during an ongoing effector response. Our data offer insights into novel strategies for rapid expansion of CD8(+) T cells using prime-boost vaccines by targeting privileged sites for Ag presentation.
引用
收藏
页码:4587 / 4595
页数:9
相关论文
共 50 条
  • [31] The whole-cell pertussis vaccine imposes a broad effector B cell response in mouse heterologous prime-boost settings
    Valeri, Viviana
    Sochon, Akhesa
    Cousu, Clara
    Chappert, Pascal
    Lecoeuche, Damiana
    Blanc, Pascal
    Weill, Jean-Claude
    Reynaud, Claude-Agnes
    JCI INSIGHT, 2022, 7 (21)
  • [32] TETRAVALENT DENGUE HETEROLOGOUS PRIME-BOOST VACCINATION - SAFETY, HUMORAL, AND CELL-MEDIATED IMMUNITY AT 1 AND 6 MONTHS
    Lin, Leyi
    Paolino, Kristopher M.
    Jarman, Richard G.
    Eckels, Kenneth H.
    De La Barrera, Rafael
    Currier, Jeffrey R.
    Friberg-Robertson, Heather L.
    Sklar, Marvin J.
    Aronson, Naomi E.
    Sondergaard, Erica L.
    Keiser, Paul B.
    Jasper, Louis E.
    Thomas, Stephen J.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 95 (05): : 20 - 20
  • [33] Heterologous prime-boost immunizations with different Salmonella serovars for enhanced antigen-specific CD8 T-cell induction
    Domenech, Victoria E. Sevil
    Panthel, Klaus
    Winter, Sebastian E.
    Ruessmann, Holger
    VACCINE, 2008, 26 (15) : 1879 - 1886
  • [34] Prime-Boost Vaccination with rBCG/rAd35 Enhances CD8+ Cytolytic T-Cell Responses in Lesions from Mycobacterium Tuberculosis-Infected Primates
    Rahman, Sayma
    Magalhaes, Isabelle
    Rahman, Jubayer
    Ahmed, Raija K.
    Sizemore, Donata R.
    Scanga, Charles A.
    Weichold, Frank
    Verreck, Frank
    Kondova, Ivanela
    Sadoff, Jerry
    Thorstensson, Rigmor
    Spangberg, Mats
    Svensson, Mattias
    Andersson, Jan
    Maeurer, Markus
    Brighenti, Susanna
    MOLECULAR MEDICINE, 2012, 18 (04) : 647 - 658
  • [35] Prime-Boost Vaccination with rBCG/rAd35 Enhances CD8+ Cytolytic T-Cell Responses in Lesions from Mycobacterium Tuberculosis-Infected Primates
    Sayma Rahman
    Isabelle Magalhaes
    Jubayer Rahman
    Raija K. Ahmed
    Donata R. Sizemore
    Charles A. Scanga
    Frank Weichold
    Frank Verreck
    Ivanela Kondova
    Jerry Sadoff
    Rigmor Thorstensson
    Mats Spångberg
    Mattias Svensson
    Jan Andersson
    Markus Maeurer
    Susanna Brighenti
    Molecular Medicine, 2012, 18 : 647 - 658
  • [36] Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteins
    Cuburu, Nicolas
    Khan, Selina
    Thompson, Cynthia D.
    Kim, Rina
    Vellinga, Jort
    Zahn, Roland
    Lowy, Douglas R.
    Scheper, Gert
    Schiller, John T.
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (07) : 1467 - 1479
  • [37] Enhanced immunogenicity of CD4+ T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis
    McShane, H
    Brookes, R
    Gilbert, SC
    Hill, AVS
    INFECTION AND IMMUNITY, 2001, 69 (02) : 681 - 686
  • [38] Combined Adenovirus Vector and Hepatitis C Virus Envelope Protein Prime-Boost Regimen Elicits T Cell and Neutralizing Antibody Immune Responses
    Chmielewska, Alicja M.
    Naddeo, Mariarosaria
    Capone, Stefania
    Ammendola, Virginia
    Hu, Ke
    Meredith, Luke
    Verhoye, Lieven
    Rychlowska, Malgorzata
    Rappuoli, Rino
    Ulmer, Jeffrey B.
    Colloca, Stefano
    Nicosia, Alfredo
    Cortese, Riccardo
    Leroux-Roels, Geert
    Balfe, Peter
    Bienkowska-Szewczyk, Krystyna
    Meuleman, Philip
    McKeating, Jane A.
    Folgori, Antonella
    JOURNAL OF VIROLOGY, 2014, 88 (10) : 5502 - 5510
  • [39] Efficient control of chronic LCMV infection by a CD4 T cell epitope-based heterologous prime-boost vaccination in a murine model
    Ran He
    Xinxin Yang
    Cheng Liu
    Xiangyu Chen
    Lin Wang
    Minglu Xiao
    Jianqiang Ye
    Yuzhang Wu
    Lilin Ye
    Cellular & Molecular Immunology, 2018, 15 : 815 - 826
  • [40] Efficient control of chronic LCMV infection by CD4 T cell epitope-based heterologous prime-boost vaccination in a murine model
    He, Ran
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):